Efficacy of Favipiravir in the Treatment of Moderate COVID-19 Patients: A Randomized, Open-label, Controlled Clinical Trial

Favipiravir does not improve viral clearance in mild to moderate COVID-19 – A systematic review and meta-analysis of randomized controlled trials

“…There was only one study indicating that favipiravir significantly improved the clinical condition of COVID-19 patients with mild symptoms compared to the control group [ 18 ]. Another study did not have a subgroup analysis by severity [ 14 , 26 ].…”

“…17 studies reported at least one side effect that can be analysed in the meta-analysis [ 3 , 10 , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [23] , [24] , [25] , [26] , 28 , 29 ] ( Table S1 ). The risks of developing low haemoglobin, hyperglycemia, elevated ALT and AST, high bilirubin, elevated creatine phosphokinase, high triglycerides, and leukopenia were comparable between the favipiravir and comparator groups ( Fig.…”

Could Selenium Supplementation Prevent COVID-19? A Comprehensive Review of Available Studies

“…Among the remaining 267 pertinent publications that dealt with sele and COVID-19, there were 6 editorial letters, 211 reviews (including 88 exclu speculative ones) and 50 scientific studies. Nine studies were further excluded: three clinical supplementation studies that administered selenium together with ingredients [18,19] or drugs [20]; one was a cross-sectional analysis that actually di include COVID-19 patients [21]; three included only one patient [22][23][24]; and two not available in English [25,26]. Of the remaining 41 pertinent scientific articles, only 2 were clinical supplemen studies, 26 were clinical observational studies, 10 were ecological and 3 were g (Figure 2).…”

Efficacy and Safety of Favipiravir for the Treatment of COVID-19 Outpatients: A Systematic Review and Meta-analysis of Randomized Controlled Trials

“…A total of 9 studies were included in our meta-analysis. [8][9][10][11][12][13][14][15][16] The detailed selection process is shown in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses flowchart (see Figure 1, Supplemental Digital Content, http://links.lww.com/AJT/A139). One study included both inpatients and outpatients 10 while the rest of the studies included outpatients exclusively.…”